Pfizer says its COVID-19 vaccine is still highly effective after 6 months

Pfizer vaccine
(Image credit: JACK GUEZ/AFP via Getty Images)

The COVID-19 vaccine from Pfizer and BioNTech is highly effective against symptomatic COVID-19 for at least six months after a second dose, a new analysis has shown.

The companies on Thursday announced that in an analysis of its phase 3 study that included 927 symptomatic COVID-19 cases, the vaccine was 91.3 percent effective "measured seven days through up to six months after the second dose." It was also 100 percent effective against severe disease as defined by the CDC, as well as 95.3 percent effective against severe disease as defined by the FDA, the companies said. There were no serious safety concerns.

Additionally, Pfizer and BioNTech said the vaccine was 100 percent effective against COVID-19 cases in South Africa, where a concerning variant has been spreading.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

The analysis comes after a CDC study earlier this week showed the Pfizer and Moderna COVID-19 vaccines to be highly effective at preventing infections in real-world conditions, as well as after Pfizer said Wednesday a trial showed its vaccine to be 100 percent effective in adolescents aged 12 to 15.

"It is an important step to further confirm the strong efficacy and good safety data we have seen so far, especially in a longer-term follow-up," BioNTech CEO Ugur Sahin said. "These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor to reach herd immunity and end this pandemic for the global population."

To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Brendan Morrow

Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.